Gas-X, 125 mg recall — Haleon US Holdings LLC (Class II)

Haleon US Holdings LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling Gas-X, 125 mg — a Class II recall, initiated 2026-05-11 and posted to the FDA enforcement report on 2026-05-27, under recall number D-0542-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Labeling: Not Elsewhere Classified- Incomplete inactive ingredient information on the carton labeling.”. From the product description, the form is softgels, the strength given is 125 mg and the package is described as 120 SoftGels. The record carries UPC 300674350419 rather than an NDC. Distribution is recorded as “U.S. Nationwide” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 98910. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0542-2026
FDA event ID 98910
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Haleon US Holdings LLC
Recall initiated 2026-05-11
Reported by FDA 2026-05-27
Report lag 16 days from initiation to report
Distribution U.S. Nationwide. — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Gas-X, Simethicone 125 mg/ ANTIGAS, 120 SoftGels, Distributed by: Haleon, Warren, NJ 07059, UPC: 3 00674 35041 9.

Reason reported by FDA

Labeling: Not Elsewhere Classified- Incomplete inactive ingredient information on the carton labeling.

12 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

5 identifying values matched by exact pattern in the 18-word product description above; each is a literal substring of it.

Product named Gas-X
Form Softgels
Strength 125 mg
Package 120 SoftGels
UPC 300674350419
Distributed by Haleon, Warren

Other indexed recalls from Haleon US Holdings LLC

2 indexed records name Haleon US Holdings LLC as the recalling firm, across 2 FDA events, reported 2026-05-27 to 2026-06-17. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Gas-X Extra Strength, 125 mgD-0595-2026Class I125 mg · Softgels2026-06-17

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Atomoxetine Capsules HCL, 10 mgD-0538-2026Safecor Health, LLCClass II2026-05-27
Liraglutide Injection, 18 mg/3 mLD-0541-2026Lupin Pharmaceuticals Inc.Class II2026-05-27
Estradiol Gel, 0.1%D-0543-2026Ani Pharmaceuticals, Inc.Class II2026-05-27
Erythromycin Tablets, 250 mgD-0544-2026Zydus Pharmaceuticals (usa) IncClass II2026-05-27
Erythromycin Tablets, 500 mgD-0545-2026Zydus Pharmaceuticals (usa) IncClass II2026-05-27
cimzia (certolizumab pegol)D-0546-2026Ucb Biosciences Inc.Class II2026-05-27
fentaNYL Citrate, 2,2500 mcg/50mLD-0548-2026Integradose Compounding Services LLCClass II2026-05-27
Vitamin B-Complex, 799 mcg/5mLD-0549-2026Safecor Health, LLCClass II2026-05-27

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 7 nearest to 2026-05-27 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Oasis Tears PF, 10mLD-0525-2026Oasis Medical, Inc.10mL · Eye Drops2026-05-20
Buprenorphine Hydrochloride, 0.3mg/mLD-0527-2026Endo Usa, Inc.0.3mg/mL · Injection2026-05-20
Ascend Laboratories, 25 mgD-0547-2026Ascend Laboratories, LLC25 mg · Extended-Release Tablets2026-05-20
DELFLEX, 1.5%D-0512-2026Fresenius Medical Care Holdings, Inc.1.5% · Solution2026-05-13
DELFLEX, 2.5%D-0513-2026Fresenius Medical Care Holdings, Inc.2.5% · Solution2026-05-13
Duloxetine Delayed-Release Capsules, 30 mgD-0514-2026Ajanta Pharma Ltd.30 mg · Delayed-Release Capsules2026-05-13
Duloxetine Delayed-Release Capsules, 60 mgD-0515-2026Ajanta Pharma Ltd.60 mg · Delayed-Release Capsules2026-05-13

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. This record identifies packages by UPC 300674350419 rather than by NDC.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Haleon US Holdings LLC (2 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0542-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0542-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-27
Ingested
2026-08-22
Record hash
4b38fb8ef05d19ef

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.